Dov Wexler

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

Donald S. Silverberg, Dov Wexler, Miriam Blum et al. · Journal of the American College of Cardiology · 2000 · 726 citations

Anemia, Subcutaneous Erythropoietin, Heart Failure +12

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

Donald S. Silverberg, Dov Wexler, David S. Sheps et al. · Journal of the American College of Cardiology · 2001 · 642 citations

Anemia, Subcutaneous Erythropoietin, Heart Failure +11

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure

Jacob George, Shuki Patal, Dov Wexler et al. · American Heart Journal · 2005 · 128 citations

Cardiomyopathy, Heart Failure, Cardiovascular Disease +8

Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure

Jacob George, Shuki Patal, Dov Wexler et al. · Archives of Internal Medicine · 2005 · 96 citations

The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?

Donald S. Silverberg, Dov Wexler, Adrian Iaina · Journal of Nephrology · 2004 · 91 citations